ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$74.11

Market cap

$10.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.15

Enterprise value

$11.62B

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 32

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The quick ratio has soared by 87% from the previous quarter and by 22% YoY
The gross profit is down by 43% QoQ but it is up by 14% YoY
The company's revenue fell by 43% QoQ but it rose by 14% YoY
The net income has dropped by 109% year-on-year
Arrowhead Pharmaceuticals's debt has surged by 100% QoQ and by 85% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY INO JNJ LGND

Key stats

What are the main financial stats of ARWR

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-3%
1 week
-14.37%
1 month
-0.55%
1 year
304.75%
YTD
11.63%
QTD
-9.08%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$622.01M
Gross profit
$622.01M
Operating income
-$221.9M
Net income
-$300.91M
Gross margin
100%
Net margin
-48.4%
The operating income has dropped by 174% since the previous quarter and by 87% year-on-year
The net income has dropped by 109% year-on-year
Arrowhead Pharmaceuticals's net margin has shrunk by 83% YoY
The operating margin has dropped by 65% year-on-year

Price vs fundamentals

How does ARWR's price correlate with its fundamentals

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
ARWR P/E details
P/E
N/A
P/B
16.9
P/S
16.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.69
ARWR's EPS has plunged by 58% YoY
The price to book (P/B) is 52% higher than the last 4 quarters average of 11.1 and 32% higher than the 5-year quarterly average of 12.8
The equity has contracted by 10% YoY but it has grown by 8% from the previous quarter
The price to sales (P/S) is 112% more than the last 4 quarters average of 8.0 but 85% less than the 5-year quarterly average of 110.7
The company's revenue fell by 43% QoQ but it rose by 14% YoY

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 151% QoQ and by 90% YoY
ARWR's ROS has plunged by 111% YoY
The company's return on assets fell by 45% YoY
The company's return on equity fell by 20% YoY

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 36% higher than its total liabilities
The total liabilities has surged by 88% year-on-year and by 60% since the previous quarter
The quick ratio has soared by 87% from the previous quarter and by 22% YoY
Arrowhead Pharmaceuticals's debt is 124% higher than its equity
The debt to equity has soared by 107% YoY and by 85% from the previous quarter
Arrowhead Pharmaceuticals's debt has surged by 100% QoQ and by 85% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.